Novo Nordisk A/S entered a licensing agreement with reMYND nv to develop its preclinical diabetes treatment.
The Danish heavyweight would potentially pay up to €350 million in research and milestone payments for ReS39, plus royalties.
ReS39 has been shown to sustain and increase the insulin production capacity of the pancreas in animals with type 1 and type 2 diabetes. The program also has the potential to treat nonalcoholic steatohepatitis — a chronic liver disease known as NASH — and metabolic syndrome because it reduces liver weight and triglyceride content.
The treatment is being profiled so that researchers can undertake preclinical toxicology studies.
reMYND was founded as a spinoff from Belgium's University of Leuven in 2002.
